Mohammadi S.,Tehran University of Medical Sciences |
Hosseinzadeh Attar M.J.,Tehran University of Medical Sciences |
Karimi M.,Tehran University of Medical Sciences |
Hosseinnezhad A.,Tehran University of Medical Sciences |
And 5 more authors.
Journal of Zanjan University of Medical Sciences and Health Services | Year: 2010
Background and Objective: Adiponectin is a novel adipose tissue-specific adipokine that can increase insulin sensitivity. Many studies have shown anti obesity and anti diabetic effects of green tea consumption. In this study we examined the effects of green tea extract on circulating adiponectin levels and insulin resistance status in patients with type 2 diabetes mellitus (T2DM). Materials and Methods: In this double blind randomized clinical trial 58 type 2 diabetic patients with BMI ≥ 25 were recruited from an unselected population from the outpatient clinic of Shariati Hospital, Tehran, Iran. Patients were randomly divided into two groups; green tea extract and placebo. All the patients received the capsules for 8 weeks. Laboratory measurements including fasting serum adiponectin, insulin, HOMA-IR, FPG, OGTT, HbA1c and lipid profile and anthropometric were performed before and after the intervention. Nutrient intakes were obtained via 24- hour recall from each patient in three successive days. The data were analyzed using appropriate software. Results: We found a significant effect of green tea extract on increasing the logarithm of serum adiponectin in diabetic patients (0.15±0.10 μg/ ml, P < 0.05). A significant independent correlation between the logarithm of serum adiponectin and WHR (Waist to Hip Ratio) was found (P= 0.009, t= -2.7). The consumption of green tea extract had a significant effect in control the levels of HbA1C, weigh and also BMI in green tea group (P < 0.05). Conclusion: The results showed that consumption of green tea extract can be useful in the control of T2DM by increasing the levels of serum adiponectin and controlling the weight, BMI and HbA1C levels in patients with T2DM.
Motlagh A.,Shahid Beheshti University of Medical Sciences |
Motlagh A.,Center for Non Communicable Disease |
Yaraei N.,Shahid Beheshti University of Medical Sciences |
Mafi A.R.,Sepas Organization |
And 19 more authors.
Archives of Iranian Medicine | Year: 2014
Objectives: There is still contradictory evidence on disclosure preferences regarding cancer diagnosis. The aim of this study was to evaluate the preference of cancer patients for knowing the truth about their disease, as well as the factors that might have an impact on these preferences. Method: This study was conducted in 11 cancer centers in Iran. A questionnaire was used to collect data, and all patients above 15 years of age who were willing to participate were included in the study. The patients were asked if they were aware of the malignant nature of their disease, and if they came to know about their disease at the time of initial diagnosis, or later. The patients were then asked about the way they looked upon their disease. In the final part of the questionnaire, the participants were asked the level of involvement they prefer to have in making treatment decisions. Results: In total, 1226 patients were enrolled in this study, only 565 (46.7%) of whom were aware of their disease at the time of diagnosis, and 878 (72.7%) at the time of interview, while 980 (85.2%) were willing to receive information about their disease. Patients' awareness was significantly associated with age under 50 years, female gender, having breast, skin or head and neck cancer, and having medical care in Shiraz or Hamadan while it was not associated with the stage or accompanying illness. Conclusion: While the majority of Iranian cancer patients prefer to be aware of the nature of their disease and have an active role in treatment decision making, they do not receive this information.
Biglarian A.,University of Social Welfare and Rehabilitation Sciences |
Bakhshi E.,University of Social Welfare and Rehabilitation Sciences |
Gohari M.R.,Tehran University of Medical Sciences |
Khodabakhshi R.,Fayazbakhsh Hospital
Asian Pacific Journal of Cancer Prevention | Year: 2012
Background and Objectives: Artificial neural networks (ANNs) are flexible and nonlinear models which can be used by clinical oncologists in medical research as decision making tools. This study aimed to predict distant metastasis (DM) of colorectal cancer (CRC) patients using an ANN model. Methods: The data of this study were gathered from 1219 registered CRC patients at the Research Center for Gastroenterology and Liver Disease of Shahid Beheshti University of Medical Sciences, Tehran, Iran (January 2002 and October 2007). For prediction of DM in CRC patients, neural network (NN) and logistic regression (LR) models were used. Then, the concordance index (C index) and the area under receiver operating characteristic curve (AUROC) were used for comparison of neural network and logistic regression models. Data analysis was performed with R 2.14.1 software. Results: The C indices of ANN and LR models for colon cancer data were calculated to be 0.812 and 0.779, respectively. Based on testing dataset, the AUROC for ANN and LR models were 0.82 and 0.77, respectively. This means that the accuracy of ANN prediction was better than for LR prediction. Conclusion: The ANN model is a suitable method for predicting DM and in that case is suggested as a good classifier that usefulness to treatment goals.
Gohari M.R.,Tehran University of Medical Sciences |
Khodabakhshi R.,Fayazbakhsh Hospital |
Shahidi J.,Elisabeth Bruyere Research Institute |
Fard Z.M.,Tehran University of Medical Sciences |
And 3 more authors.
Tumori | Year: 2012
Aims and background. Identifying the risk factors of recurrence of breast cancer is important for both the physician and patient. Analysis of the first recurrence may lead to an inaccurate evaluation of the factor's effects because it does not completely reflect the history of the disease and may result in the loss of valuable information. The present study aimed to determine the factors that influence breast cancer recurrence and to estimate disease-free survival, adjusting for multiple metastases in breast cancer patients. Methods and study design. Patients were selected from a longitudinal study carried out at Fayazabakhsh Hospital in Tehran, Iran. Women who were diagnosed with breast cancer and who underwent either modified radical mastectomy or breast-conserving surgery between January 2006 and April 2008 were recruited to take part in the study. Breast cancer recurrence was defined as the occurrence of a tumor in the contralateral breast, local-regional relapse, or distant metastasis to other organs. Using an extended Cox model, the effect of age, tumor size, estrogen receptors, HER2, progesterone receptors as well as lymph node ratio was analyzed. Results. Over a 5833 person-month follow-up, 25 of 133 patients (18.8%) had died and 108 patients (81.2%) were still alive, 9 of them with metastasis. Thirty-four patients (25.6%) experienced their first disease recurrence. A total of 11 patients had a second metastasis. The mean time to first metastasis was 19.93 months, and mean gap time between two metastases was 7.15 months. Risk of experiencing a metastasis or death in the third and fifth year after surgery was approximately 22% and 28%, respectively. Fitting multiple recurrent regression shows that high lymph node ratio, high histologic grade, large tumor size and HER2-positive tumors are prognostic factors for shorter disease-free survival. Conclusions. Our novel approach might be helpful in clinical practice to predict breast cancer recurrence after surgery and might be adapted to be used in other malignancies as well. © Il Pensiero Scientifico Editore.
Zendehdel N.,Iran National Institute of Genetic Engineering and Biotechnology |
Biramijamal F.,Iran National Institute of Genetic Engineering and Biotechnology |
Hossein-Nezhad A.,Tehran University of Medical Sciences |
Zendehdel N.,Shahid Beheshti University of Medical Sciences |
And 3 more authors.
Archives of Iranian Medicine | Year: 2010
Background: There are different clinical responses to omeprazole treatment in Iranian patients with gastroesophageal reflux disease. Omeprazole is metabolized in the liver by the cytochrome p450 2c19 (CYP2C19) enzyme. Two common polymorphisms of the CYP2C19 gene affect CYP2C19 enzyme activity. We investigated the effect of CYP2C19 gene polymorphisms on the clinical response to treatment with omeprazole in Iranian patients with erosive reflux esophagitis. Methods: Eighty-two Iranian patients with reflux esophagitis were enrolled in the study and underwent treatment with omeprazole at 40 mg daily for 4 weeks. A 2 mL sample of venous blood was obtained from each subject. CYP2C19 genetic polymorphisms were detected using the PCR-RFLP method. The patients were grouped into homo-extensive metabolizers and hetero-extensive metabolizers based on their CYP2C19 polymorphism. The grade of esophagitis was determined via endoscopy. The symptoms score was assessed at the beginning of treatment. Results: Our results showed that the rate of complete clinical response to treatment with omeprazole was 95% in the hetero-extensive metabolizers group, which was higher than in the homo-extensive metabolizers group (P<0.001). Conclusion: CYP2C19 polymorphism influences the therapeutic efficacy of omeprazole in the treatment of Iranian patients with erosive reflux esophagitis. The clinical response and endoscopic healing of esophagitis are both affected by CYP2C19 genotype condition.